Latest news with #TimDyer
Yahoo
12-05-2025
- Business
- Yahoo
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND enabling studies. This is the final preclinical development stage before clinical studies can be started. 'Our partner Indivior has made great progress with their GABAB PAM substance use disorders program, successfully completing the last preclinical safety and toxicity studies with the compound they selected from our research collaboration. This significant achievement demonstrates the quality of the compounds discovered by the Addex team,' said Tim Dyer, CEO of Addex. 'Our own GABAB PAM cough program is also advancing through preclinical studies and is scheduled to start IND enabling studies later this year.' As previously announced, Indivior has selected a GABAB PAM for future development in substance use disorders as part of a research collaboration between the two companies. Under the terms of the agreement, Addex is eligible for payments of up to USD 330 million on successful achievement of prespecified regulatory, clinical and commercial milestones as well as tiered royalties on the level of net sales from high single digits up to low double-digit. As part of the same agreement, Addex has selected a compound for it own independent GABAB PAM program and is advancing this program for the treatment of chronic cough. About GABAB Activation with PAM:Activation of gamma-aminobutyric acid subtype B (GABAB) receptor, a Family C class of GPCR, is clinically and commercially validated. The generic GABAB receptor agonist, baclofen, marketed for spasticity, has been shown to be efficacious in several other disease areas, including alcohol use disorder, CMT1A, overactive bladder, chronic cough and pain. However, its wider use is limited due to a variety of side effects, rapid clearance and the development of tolerance. Novel, potent, selective and orally available PAMs that potentiate GABA responses, rather than acting as orthosteric agonists at the GABAB receptor, like baclofen, are expected to deliver efficacy and have fewer adverse effects. Furthermore, PAMs only act when the natural ligand (GABA) activates the receptor, hence respecting the physiological cycle of activation, which may explain why PAMs lead to less tolerance than direct agonists. About Addex Therapeutics Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@ Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.
Yahoo
30-04-2025
- Business
- Yahoo
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with Sinntaxis AB ( for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5 (mGlu5) inhibitors for the treatment of brain injury recovery. The agreement also includes a research collaboration under which the Sinntaxis team will complete evaluation of Addex's dipraglurant, an orally active mGlu5 negative allosteric modulator (NAM), for the treatment of brain injury recovery. 'Dipraglurant is a key clinical asset for Addex and this agreement with Sinntaxis is key to our strategy to reposition dipraglurant in this significant unmet medical need. Under the collaboration, we will complete the preclinical validation of dipraglurant in models of brain injury recovery building on the data already published in Brain last year,' said Tim Dyer, CEO of Addex. 'Our previous clinical studies in other indications have shown dipraglurant to be safe, well tolerated and highly selective towards the mGlu5 receptor, so we believe it could be a promising clinical candidate to treat functional recovery in patients including those with stroke or traumatic brain injury.' Under the terms of the agreement, Addex will pay Sinntaxis an undisclosed option fee to obtain an exclusive license to access intellectual property rights that Sinntaxis holds covering the use of mGlu5 NAMs to improve recovery of function in patients suffering from brain damage or injury as the result of a stroke or other brain trauma. The agreement also includes a collaboration under which Sinntaxis will execute a research plan to complete the preclinical evaluation and contribute expertise in designing clinical plans. 'With dipraglurant, Addex has a promising candidate ready for clinical evaluation to help patients with brain injury recover better. We have been evaluating the role that the mGlu5 receptor plays in modulating brain plasticity and function for some time and are looking forward to adding our expertise to the development acumen of Addex so that we can move quickly towards clinical evaluation,' said Tadeusz Wieloch, CEO of Sinntaxis. About mGluR5 NAMs and Brain InjuryFunctional recovery following stroke relies on the formation of new or reactivation of existing neural connections. Accumulating evidence suggests that the mGlu5 receptor modulates brain plasticity and function. A paper published in BRAIN*, titled 'Inhibiting metabotropic glutamate receptor 5 after stroke restores brain function and connectivity', showed that daily treatment with mGlu5 NAMs for 12 days, starting 2 or 10 days after stroke, restored lost somatosensory functions without diminishing infarct size. Within hours of treatment, somatosensory recovery expressed in normalized use of affected limbs, was apparent and progressed for the subsequent 12 days. Furthermore, brain-wide disruptions in resting-state functional connectivity after stroke were reversed by mGlu5 inhibition in distinct sensorimotor cortices contralateral to the lesion and bilaterally in visual cortices. * Brain, Volume 147, Issue 1, January 2024, Pages 186–200 About Addex: Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55PR@ Mike SinclairPartner, Halsin Partners+44 7968 022075msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2023, as filed with the SEC on April 18, 2024, the final prospectus supplement and accompanying prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking in to access your portfolio
Yahoo
26-04-2025
- Business
- Yahoo
Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Highlights: Strategic Spinout and Financial ...
Series A Financing: USD65 million raised for Neurosterix, led by Perceptive Advisors. Cash Received: CHF5 million in cash from the Neurosterix transaction. Equity Interest: 20% equity interest in Neurosterix. Cash Balance: CHF3.3 million at the end of 2024. Revenue: CHF400,000 in 2024, down from CHF1.6 million in 2023. R&D Expenses: CHF0.8 million for continuing operations in 2024. G&A Expenses: CHF2.3 million for continuing operations in 2024. Net Loss from Associates: CHF2.2 million related to the 20% equity interest in Neurosterix. Current Liabilities: CHF0.8 million as of December 31, 2024. Noncurrent Liabilities: CHF0.2 million as of December 31, 2024. Warning! GuruFocus has detected 6 Warning Signs with ADXN. Release Date: April 25, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Addex Therapeutics Ltd (NASDAQ:ADXN) successfully launched Neurosterix with a USD65 million Series A financing, securing CHF5 million in cash and a 20% equity interest. The GABAB PAM program made significant progress, with Indivior selecting a compound for development in substance use disorders and starting IND-enabling studies. Addex Therapeutics Ltd (NASDAQ:ADXN) regained rights to the Phase II asset ADX71149 from Johnson & Johnson, providing a high-value data set and significant materials. The company has a strong patent position and a ready drug product for dipraglurant, which is being repositioned for brain injury recovery. Addex Therapeutics Ltd (NASDAQ:ADXN) has a cash runway through mid-2026, with reduced cash burn following the Neurosterix spinout transaction. Current cash does not fund the progression of unpartnered programs into the clinic, indicating a need for additional financing. The completion of the funded research phase with Indivior led to a decrease in recognized income from CHF1.6 million in 2023 to CHF400,000 in 2024. Continuing R&D expenses primarily related to the GABAB PAM program decreased, reflecting the completion of the research phase of the Indivior collaboration. The company faces challenges in raising significant capital due to its low market capitalization, which could be highly dilutive to shareholders. Addex Therapeutics Ltd (NASDAQ:ADXN) has divested its allosteric modulator technology platform and the majority of its staff to Neurosterix, potentially impacting internal capabilities. Q: Could you provide more details about Neurosterix and its projects? A: Tim Dyer, CEO of Addex Therapeutics, explained that Neurosterix was founded as a spin-out from Addex, including their platform, facilities, and staff. It was sold to a US LLC with a $65 million capital commitment from investors led by Perceptive Advisors. Addex retains a 20% interest. Neurosterix focuses on neuropsychiatry with four programs: a muscarinic M4 PAM, an mGluR7 negative modulator, an mGluR2 negative allosteric modulator, and an undisclosed early-stage program. Q: How do you see the strategic environment evolving for dipraglurant in neuro rehabilitation? A: Mikhail Kalinichev, Head of Translational Science, stated that dipraglurant has shown good tolerability and will be tested in clinical pharmacology studies to assess its impact on neuroplasticity. Initial studies will be conducted with healthy volunteers, followed by post-stroke patients, to confirm its potential in enhancing rehabilitation outcomes. Q: What impact does the failure of the Phase III trial of Cobenfy have on your strategy for Neurosterix's assets? A: Mikhail Kalinichev noted that the failure has minimal impact on their strategy. They remain confident in the muscarinic M4 target for psychosis and continue to pursue monotherapy approaches. Q: What are your plans for the compound returned from J&J? A: Tim Dyer mentioned that Addex is evaluating the compound, which has a significant amount of data and material. They are in discussions with potential partners to explore development opportunities for this high-quality asset. Q: Does Addex have additional responsibilities in managing Neurosterix due to its 20% investment? A: Tim Dyer clarified that Neurosterix operates independently with its own team, which includes former Addex staff. He serves as CEO for both companies under a service agreement, ensuring strategic alignment without direct management responsibilities. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
25-04-2025
- Business
- Yahoo
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Repositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recovery Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 25, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2024 financial results for the period ended December 31, 2024 and provided a corporate update. 'During 2024, we have continued to progress clinical development of key clinical assets and build on the momentum resulting from the launch of Neurosterix,' said Tim Dyer, CEO of Addex. 'Importantly, our partner Indivior selected drug candidates for further development in substance use disorders, which enable us to select and characterize our own GABAB PAM for further development in chronic cough. We have also made significant progress with dipraglurant, repositioning in brain injury recovery. Finally, we are now evaluating the future development of ADX71149, our mGlu2 PAM after regaining full control of this asset.' Operating Highlights: Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to accelerate the development of a preclinical portfolio including M4 PAM for schizophrenia; Received CHF 5.0 million and 20% of equity interest in Neurosterix; Successfully completed funded research phase of the Indivior collaboration with both Indivior and Addex each selecting GABAB PAM drug candidate for further development in SUD and chronic cough, respectively; Repositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recovery Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Key 2024 Financial Data CHF' thousands 2024 2023* Change Income 410 1,617 (1,207) R&D expenses (854) (1,187) 333 G&A expenses (2,311) (2,673) 362 Total operating loss (2,755) (2,243) 512 Finance result, net 23 (257) 280 Share of net loss of associates (2,177) - (2,177) Net loss from continuing operations (4,909) (2,500) (2,409) Net profit / (loss) from discontinued operations 11,965 (8,056) 20,021 Net profit / (loss) for the period 7,056 (10,556) 17,612 Basic net profit / (loss) per share 0.07 (0.14) 0.21 Diluted net profit / (loss) per share 0.04 (0.14) 0.18 Net decrease in cash and cash equivalents (523) (3,092) 2,569 Cash and cash equivalents 3,342 3,865 (523) Shareholders' equity 9,677 1,145 8,532 * The comparative information has been re-presented due to discontinued operations that have been reclassed to the financial line called 'Net profit or loss from discontinued operations' following Neurosterix transaction. Financial Summary: Under IFRS, the sale of our allosteric modulator drug discovery platform and unpartnered preclinical portfolio to Neurosterix on April 2, 2024, required the identification of continuing operations related to retained programs by the Group and discontinued operations, including the net gain from the sale of a part of our business and discontinued operating activities related to income and expenses of divested activities by the Group during 2024 and 2023 periods, respectively. The net gain from the sale of a part of our business, the income and expenses from discontinued operating activities have been reclassed to the financial line called 'Net profit or loss from discontinued operations.' During the 2024 period, net profit from discontinued operations amounted to CHF 12.0 million, and was primarily related to the net gain of CHF 13.9 million from the sale of part of our business, partially offset by the net loss of CHF 1.9 million from discontinued operating activities. During the 2023 period, the Group incurred a net loss from discontinued operations of CHF 8.1 million. During the 2024 period, net profit amounted to CHF 7.1 million, primarily related to the net profit from discontinued operations of CHF 12.0 million partially offset by the net loss from continuing operations of CHF 4.9 million. During the 2023 period, the Group incurred a net loss of CHF 10.6 million of which CHF 8.1 million was related to operating discontinued activities. Diluted net gain per share amounted to CHF 0.04 for 2024, compared to a diluted net loss per share of CHF 0.14 for 2023. Cash and cash equivalents decreased to CHF 3.3 million at December 31, 2024, compared to CHF 3.9 million at December 31, 2023. The decrease of CHF 0.6 million between December 31, 2024 and December 31, 2023 is primarily due to the cash used in operating activities, partially offset by gross proceeds of CHF 5.0 million from the Neurosterix Transaction received in April 2024. All financial variances described below relate to continuing operations: Income is primarily driven by amounts received under our funded research collaboration with Indivior, recognized as related costs are incurred. In 2024, income decreased by CHF 1.2 million to CHF 0.4 million in 2024 compared to CHF 1.6 million in 2023, primarily due to the completion of the research agreement on June 30, 2024. On August 27, 2024, Indivior selected a compound for future development in substance use disorder and undertakes all future development of its selected compound. R&D expenses primarily relate to our GABAB PAM program and decreased by CHF 0.3 million to CHF 0.8 million in 2024 compared to CHF 1.2 million in 2023, primarily due to the completion of the research agreement with Indivior on June 30, 2024. G&A expenses decreased by CHF 0.4 million to CHF 2.3 million in 2024 compared to CHF 2.7 million in 2023, primarily due to reduced D&O insurance costs. The net loss from continuing operations increased by CHF 2.4 million to CHF 4.9 million in 2024 compared to CHF 2.5 million in 2023, primarily due to reduced revenue and increased costs related to the share of the net loss of the Neurosterix Group. 2024 Consolidated Financial Statements:The full-year 2024 financial report can be found on the Company's website in the investor/download section here. Conference Call Details:A conference call will be held today, April 25, 2025, at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to review the financial results. Tim Dyer, Chief Executive Officer and Mikhail Kalinichev, Head of Translational Science will deliver a brief presentation followed by a Q&A session. Joining the Conference Call: Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN. In the 10 minutes prior to the call's start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number. Webcast registration URL: Conference call registration URL: About Addex Therapeutics:Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@ Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.
Yahoo
24-04-2025
- Business
- Yahoo
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Full-Year 2024 Financial Results on April 25, 2025. Tim Dyer, CEO, and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day. Title: Addex Therapeutics Full-Year 2024 financial results and corporate update Date: April 25, 2025Time: 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) Joining the Conference Call: Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN. In the 10 minutes prior to the call's start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number. Webcast registration URL: call registration URL: About Addex: Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex's partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol 'ADXN' on each exchange. For more information, visit Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55PR@ Mike SinclairPartner, Halsin Partners+44 7968 022075msinclair@ Addex Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking in to access your portfolio
